28 – 29 June 2021


University of BernMittelstrasse 43



Goals of the module


  • have an overview on sex differences in oncology and the scientific, clinical and societal implications of sex differences for prevenetion, diagnosis and treatment of cancer.
  • are familiar with the combined impact of sexual hormones and sex chromosomes on cancer susceptibility with a focus on intrinsic control of cancer initiating cell populations, tumor microenvironment and systemic determinants of cancer development.
Content of the module
  • Rationale for considering gender in cancer prevention and treatment
        • Sex differences in epidemiology of various cancers
        • Sex and gender differences in carcinogen exposition (UV light, smoking, environmental carcinogens)
  • Sex chromosomes and their impact on cancer susceptibility
      • Estrogens and their impact on cancer risk in females and males
      • Endocrine disruptors
      • Androgens and their impact on cancer risk in females and males
  • Impact of sex on systemic determinants of cancer development
    • immunity
    • tumor microenvironment
    • cancer initiating cells
    • metabolism
    • microbiome
  • Clinical implications of sex and gender differences in cancer
    • Sex differences in response and toxicity of anticancer therapies (cytotoxics, targeted therapies and immunotherapies)
    • Sex differences in oncological surgery and radiotherapy outcomes
    • Implications for clinical trial design and reporting of results
    • Sex-specific drug dosing strategies?
    • Sex-specific cancer prevention efforts?

Dr. med. Berna Özdemir, Universitätsklinik für Medizinische Onkologie, Inselspital, Universitätsspital Bern (Chair)

Prof. Dr. Paolo Dotto, Department of Biochemistry, University of Lausanne/ International Cancer Prevention Institute

PD Dr. med. Anna Wagner, Department of Oncology, Lausanne University Hospital and University of Lausanne

Registration form and Deadline

Deadline 20 May 2021, Registration form